Medix Biochemica has announced the appointment of Petra Furu as its Chief Executive Officer, effective June 1, 2026, marking the completion of its leadership transition.

Furu joined the company in June 2025 as Vice President of the Immunoassay Business Unit. Prior to this, she held senior leadership roles at Revvity, where she most recently led the Reproductive Health business.

With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector.

Her appointment follows a transition period during which Teemu Alahuhta served as interim CEO from April 2025, after Steve Ferguson stepped down following a five-year tenure.

Over the past year, the company’s leadership team has outlined a strategy for its next phase of growth, building on its transformation journey since 2018. This roadmap is anchored in four key priorities: strengthening customer centricity, delivering high-performing and sustainable solutions, expanding in high-growth markets, and driving operational excellence.

“I am honored by the opportunity to lead Medix Biochemica through the next phase of its transformational journey and drive execution of our four must-win battles to achieve our strategic ambitions. While success will require customer centricity in every decision, focused execution, and close collaboration across the organization,” said Petra Furu, the incoming CEO of Medix Biochemica.